WO2010002966A2 - Procédé de criblage à haut débit et son utilisation pour identifier une plateforme de production d'une protéine de liaison multifonctionnelle - Google Patents

Procédé de criblage à haut débit et son utilisation pour identifier une plateforme de production d'une protéine de liaison multifonctionnelle Download PDF

Info

Publication number
WO2010002966A2
WO2010002966A2 PCT/US2009/049366 US2009049366W WO2010002966A2 WO 2010002966 A2 WO2010002966 A2 WO 2010002966A2 US 2009049366 W US2009049366 W US 2009049366W WO 2010002966 A2 WO2010002966 A2 WO 2010002966A2
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
binding
region
expressing
screening
Prior art date
Application number
PCT/US2009/049366
Other languages
English (en)
Other versions
WO2010002966A3 (fr
Inventor
Diane Retallack
Original Assignee
Dow Global Technologies Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Global Technologies Inc. filed Critical Dow Global Technologies Inc.
Priority to CA2729839A priority Critical patent/CA2729839A1/fr
Priority to NZ590619A priority patent/NZ590619A/xx
Priority to EP09774416A priority patent/EP2313507A2/fr
Priority to AU2009266989A priority patent/AU2009266989B2/en
Priority to US13/001,913 priority patent/US20110111977A1/en
Publication of WO2010002966A2 publication Critical patent/WO2010002966A2/fr
Publication of WO2010002966A3 publication Critical patent/WO2010002966A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors

Definitions

  • This invention relates to methods of identifying and expressing antibody variants under high throughput conditions.
  • High-throughput screening is a key link in the chain comprising the industrialized drug discovery paradigm.
  • Today, many pharmaceutical companies are screening 100,000-300,000 or more compounds per screen to produce approximately 100-300 hits. On average, one or two of these become lead compound series. Larger screens of up to 1,000,000 compounds in several months may be required to generate something closer to five leads. Improvements in lead generation can also come from optimizing library diversity. Since the 1980s, improvements in screening technologies have resulted in throughputs that have increased from 10,000 assays per year to current levels, which can approach ultrahigh-throughput screening levels of more than 100,000 assays per day.
  • High-throughput screening is evolving not only as a discrete activity, but also as a method that is being used for target identification and validation, and finds additional application in converting assay hits to qualified leads via information generated either within screens or through downstream, high-throughput ADME (absorption, distribution, metabolism, and excretion) and toxicity testing.
  • High throughput screening has been used to identify and isolate antibodies, but only through binding of the antibodies to specific antigens, such as those present on a particular cell type, transformed or diseased cell, or a particular receptor or ligand. Identifying the best method to express an antibody variant once the binding region has been identified via phage display or other techniques can be challenging.
  • Certain embodiments of the invention include methods of identifying and expressing a binding protein, wherein the method includes fusing a binding region to a plurality of scaffolds of antibody constant regions or other structural scaffolds to obtain an array of binding protein variants, expressing the variants in a host cell to form constructs, and expressing the constructs carried by the host cells to form induced cultures, wherein the host cells are expressed in high throughput ("HTP”) mode.
  • HTP high throughput
  • Other embodiments of the invention include a method of parallel screening for candidates by identifying fusing the plurality of binding regions to one or more scaffolds, in parallel, to obtain a plurality of variants, expressing the plurality of variants in, for example, Pseudomonas fluorescens to form constructs, expressing the construct carried by P. fluorescens to form induced cultures, and evaluating the induced cultures for product candidates.
  • the binding region may be fused to the plurality of scaffolds by methods including Splicing by Overlapping Extension PCR (SOE-PCR), direct gene synthesis, and cloning of a binding region in frame with the scaffold structures present in pre-constructed vector sets
  • Another embodiment of the invention includes methods of developing binding protein product candidates by fusing a binding region of an antibody to a plurality of scaffolds in parallel to obtain variants, expressing the variants in, e.g., P fluorescens to form constructs, and expressing the constructs carried by the host cells to form induced cultures, wherein the cells are expressed in HTP mode.
  • the method includes starting with at least one known binding region that was identified by a screening method, and then fusing the at least one binding region to a multitude of scaffolds and screening the resulting variants.
  • Such a method includes fusing at least one binding domain, which binding domain interacts with a target of interest, to at least one molecule selected from the group consisting of at least one of a scaffold, another binding domain, and a functionalized domain; cloning the fused binding domain into a plurality of plasmids, each plasmid comprising various expression signals; transforming a host cell with the thus cloned plasmids; and simultaneously expressing transformants in the host cell in a high throughput manner and screening expressed fusions for antigen-binding activity so as to identify a structure able to bind the target of interest and expression plasmid or host cell therefor.
  • the method can be repeated in one or more of its elements.
  • the molecule can be, among other things, a functionalized domain selected from the group consisting of a stability functionalized domain, a solubility functionalized domain, and a combination thereof.
  • the molecule can be, among other things, a scaffold selected from the group consisting of an antibody constant region, a non-antibody natural or non-natural stabilizing structure, an additional binding domain derived from an antibody, and an additional non-antibody derived binding domain.
  • the expression signals can be, among other things, selected from the group consisting of a transcription signal, a translation signal, a protein secretion signal, and any combination thereof.
  • the at least one binding domain can be, among other things, derived from an antibody- VH region, an antibody- VL region, a non-antibody binding protein of natural or non- natural origin, a fibronectin derivative, adnectin, ankyrin repeat protein, lipocalin, a protein A derivative, a gamma crystalline derivative, a transferrin derivative, and a synthetic peptide with immunoglobulin like folds.
  • the binding domain preferably interacts with a particular target and is identified by a variety of sources comprising sources selected from the group consisting of a randomly generated library, screening B cells, screening T cells, screening sera, and combinations of any thereof.
  • the interaction with a particular target can be identified by, among other things, bio-panning, panning, and/or display methods.
  • the binding region can be fused to a scaffold by Splicing by Overlapping Extension PCR (SOE-PCR), gene synthesis, and cloning into pre-constructed vectors with scaffold coding region in correct translational reading frame.
  • SOE-PCR Overlapping Extension PCR
  • An expression plasmid can include an inducible promoter, Ptac, or Pmannitol, a translation initiation site, a transcription terminator, and, optionally, a secretion signal. Transformation of an expression plasmid into the host cell can generate an array of production strains comprises expressing a variety of binding structures so as to simultaneously screen for titer and functionality in a high throughput in vivo or in vitro system.
  • the host cell can be a bacterium, particularly a gram negative bacterium, such as pseudomonadaceaes, e.g., P. fluorescens.
  • the bacterium can have one or more protease genes deleted.
  • the method can further comprise co-overexpressing folding modulators.
  • the plasmids can express a single binding region fused to one or more scaffolds. In alternative embodiments, the plasmids can express more than one binding region fused to one or more scaffolds.
  • the hosts cells are grown and induced in a high throughput manner ⁇ e.g., using a multi-well well plate and/or growth of production strains in parallel).
  • Such methods may include evaluating protein - protein interaction(s) by an in vitro and/or in vivo assay.
  • the in vitro or in vivo assay can be an assay selected from the group consisting of ELISA, RIA, biolayer interferometry (such as Octet), surface plasmon resonance, two hybrid systems, cell based assay, and combinations thereof.
  • the method further includes screening activity in a high throughput manner.
  • Particular embodiments of the method further include simultaneously screening for a production host cell that expresses a high titer of fusion having a desired function or quality.
  • the method may also further include activity testing of the fusion in an animal model.
  • the method may further include identifying a candidate with a desired bioavailability, half-life, and/or reduced immunogenicity in a subject.
  • the method further includes screening antibody derivatives.
  • Alternative embodiments of the method further include screening libraries of non-natural binding proteins.
  • the method further includes screening derivatives of non-antibody binding proteins derived from naturally occurring proteins.
  • FIG. 1 is a graphical representation of histogram of optical density readings at 600nm of HTP cultures taken 24 hours post induction;
  • FIG. 2 is a graphical representation of HTP expression of anti- ⁇ -galactosidase antibody derivatives
  • FIG. 3 is a graphical representation of an antibody expression vector
  • FIG. 4 is a graphical representation of anti-fluorescein antibody HTP expression
  • FIG. 5 is a graphical representation of product design for antibody derivative binding proteins.
  • Embodiments of the present invention provide methods of identifying and expressing an antibody variant that include identifying a binding region in an antibody, fusing the binding region to a plurality of scaffolds of antibody constant regions to obtain antibody fragment variants, expressing the antibody fragment variants in organisms to form constructs, and expressing the constructs carried by the organisms to form induced cultures, wherein the organisms are expressed in HTP mode.
  • antibody is used in the broadest sense and includes monoclonal antibodies, polyclonal antibodies, multivalent antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments so long as they exhibit the desired biological activity.
  • a naturally occurring antibody comprises four polypeptide chains, two identical heavy (H) chains and two identical light (L) chains inter-connected by disulfide bonds.
  • Each heavy chain is comprised of a heavy chain variable region (VH) and a heavy chain constant region, which in its native form is comprised of three domains, CHl, CH2 and CH3.
  • Each light chain is comprised of a light chain variable region (VL) and a light chain constant region.
  • the light chain constant region is comprised of one domain, CL.
  • VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR).
  • CDR complementarity determining regions
  • FR framework regions
  • Each VH and VL is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FRl, CDRl, FR2, CDR2, FR3, CDR3, and FR4.
  • the light chains of antibodies from any vertebrate species can be assigned to one of two clearly distinct types, called kappa (K) and lambda (A), based on the amino acid sequences of their constant domains.
  • antibodies can be assigned to different classes.
  • immunoglobulins There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgG-I, IgG-2, IgA-I, IgA-2, and etc.
  • the heavy chain constant domains that correspond to the different classes of immunoglobulins are called ⁇ , ⁇ , ⁇ , ⁇ , and ⁇ , respectively.
  • An antibody may be part of a larger fusion molecule, formed by covalent or noncovalent association of the antibody or antibody portion with one or more other proteins or peptides.
  • fusion proteins include use of the streptavidin core region to make a tetrameric scFv molecule (Kipriyanov et al.
  • the term "monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigen. Furthermore, in contrast to polyclonal antibody preparations that typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen.
  • the monoclonal antibodies herein specifically include "chimeric" antibodies in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (U.S. Patent No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA 8 1 :685 1-6855 (1984)).
  • a “functional” or “biologically active” antibody is one capable of exerting one or more of its natural activities in structural, regulatory, biochemical or biophysical events.
  • a functional antibody may have the ability to specifically bind an antigen and the binding may, in turn, elicit or alter a cellular or molecular event such as signaling transduction or enzymatic activity.
  • a functional antibody may also block ligand activation of a receptor or act as an agonist antibody.
  • the capability of an antibody to exert one or more of its natural activities depends on several factors, including proper folding and assembly of the polypeptide chains.
  • the functional antibodies generated by the disclosed methods are typically heterotetramers having two identical L chains and two identical H chains that are linked by multiple disulfide bonds and properly folded.
  • embodiments of the present invention encompass blocking antibodies, antibody antagonists and/or antibody agonists.
  • a "blocking" antibody or an antibody “antagonist” is one which inhibits or reduces biological activity of the antigen it binds. Such blocking can occur by any means, e.g., by interfering with: ligand binding to the receptor, receptor 10 complex formation, tyrosine kinase activity of a tyrosine kinase receptor in a receptor complex and/or phosphorylation of tyrosine kinase residue(s) in or by the receptor.
  • a VEGF antagonist antibody binds VEGF and inhibits the ability of VEGF to induce vascular endothelial cell proliferation.
  • an "antibody agonist” is an antibody which binds and activates antigen, such as a receptor.
  • the receptor activation capability of the agonist antibody will be at least qualitatively similar (and may be essentially quantitatively similar) to a native agonist ligand of the receptor.
  • Embodiments of the present invention are applicable to antibodies or antibody fragments of any appropriate antigen binding specificity.
  • the antibodies of the present invention may be specific to antigens that are biologically important polypeptides.
  • the antibodies of the present invention may be useful for therapy or diagnosis of diseases or disorders in a mammal.
  • the antibodies or antibody fragments obtained according to the embodiments of the present invention may be useful as therapeutic agents, such as blocking antibodies, antibody agonists or antibody conjugates.
  • Non-limiting examples of therapeutic antibodies include anti-VEGF, anti-IgE, anti-CD 11, anti-CD 18, anti-tissue factor, and anti- TrkC antibodies.
  • Antibodies directed against non-polypeptide antigens are also contemplated.
  • antigen is well understood in the art and includes substances which are immunogenic, i.e., immunogens, as well as substances which induce immunological unresponsiveness, or anergy, i.e., anergens.
  • the antigen is a polypeptide, it may be a transmembrane molecule (e.g., receptor) or ligand such as a growth factor.
  • antigens include molecules, such as renin; a growth hormone, including human growth hormone and bovine growth hormone; growth hormone releasing factor; parathyroid hormone; thyroid stimulating hormone; lipoproteins; alpha- 1 -antitrypsin; insulin A-chain; insulin B-chain; proinsulin; follicle stimulating hormone; calcitonin; luteinizing hormone; glucagon; clotting factors, such as factor VIIIC, factor IX, tissue factor (TF), and von Willebrands factor; anti- clotting factors such as Protein C; atrial natriuretic factor; lung surfactant; a plasminogen activator, such as urokinase or human urine or tissue-type plasminogen activator (t-PA); bombesin; thrombin; hemopoietic growth factor; tumor necrosis factor-alpha and -beta; enkephalinase; RANTES (regulated on activation normally T-cell expressed and secreted); human macrophage inflammatory protein
  • Antigens for antibodies encompassed by embodiments of the present invention may include, for example: CD proteins, such as CD3, CD4, CD8, CDlIa, CDlIb, CD18, CD19, CD20, CD34 and CD46; members of the ErbB receptor family, such as the EGF receptor, HER2, HER3 or HER4 receptor; cell adhesion molecules, such as LFA-I, Macl, pl50.95, VLA-4, ICAM- 1, VCAM, ⁇ 4/ ⁇ 7 integrin, and ⁇ av/ ⁇ 3 integrin including either ⁇ or ⁇ subunits thereof; growth factors, such as VEGF, tissue factor (TF), and TGF- ⁇ alpha interferon ( ⁇ -IFN); an interleukin, such as IL-8; IgE; blood group antigens Apo2; death receptor; flk2/flt3 receptor; obesity (OB) receptor; mpl receptor; CTLA-4; and protein C.
  • CD proteins such as CD3, CD4, CD8, CDl
  • Soluble antigens or fragments thereof, optionally conjugated to other molecules can be used as immunogens for generating antibodies.
  • immunogens for transmembrane molecules, such as receptors, fragments of these molecules (e.g., the extracellular domain of a receptor) can be used as the immunogen.
  • cells expressing the transmembrane molecule can be used as the immunogen.
  • Such cells can be derived from a natural source (e.g., cancer cell lines) or may be cells which have been transformed by recombinant techniques to express the transmembrane molecule.
  • Other antigens and forms thereof useful for preparing antibodies will be apparent to those in the art.
  • the antibodies according to embodiments of the present invention may be monospecific, bispecific, trispecific or of greater multispecificity.
  • Multispecific antibodies may be specific to different epitopes of a single molecule or may be specific to epitopes on different molecules. Methods for designing and making multispecific antibodies are known in the art. See, e.g., Millstein et al. (1983) Nature 305:537-539; Kostelny et al. (1992) J. Immunol. 148: 1547-1553; WO 20 93117715.
  • Embodiments of the present invention contemplate the prokaryotic or eukaryotic production of antibodies or antibody fragments. Many forms of antibody fragments are known in the art and encompassed herein. "Antibody fragments" comprise only a portion of an intact antibody, generally including an antigen binding site of the intact antibody and thus retaining the ability to bind antigen.
  • antibody fragments encompassed by the present definition include: (i) the Fab fragment, having VL, CL, VH and CHl domains; (ii) the Fab' fragment, which is a Fab fragment having one or more cysteine residues at the C-terminus of the CHl domain; (iii) the Fd fragment having VH and CHl domains; (iv) the Fd' fragment having VH and CHl domains and one or more cysteine residues at the C-terminus of the CHl domain; (v) the Fv fragment having the VL and VH domains of a single arm of an antibody; (vi) the dAb fragment (Ward et al., Nature 341, 544-546 (1989)) which consists of a VH domain; (vii) isolated CDR regions; (viii) F(ab') 2 fragments, a bivalent fragment including two Fab' fragments linked by a disulfide bridge at the hinge region; (ix) single chain antibody molecules (e.g., single chain
  • embodiments of the present invention may include antibody fragments that are modified to improve their stability and or to create antibody complexes with multivalency.
  • antibody fragments must be sufficiently stable against denaturation or proteolysis conditions, and the antibody fragments should ideally bind the target antigens with high affinity.
  • a variety of techniques and materials have been developed to provide stabilized and or multivalent antibody fragments.
  • An antibody fragment may be fused to a dimerization domain.
  • the antibody fragments of the present invention are dimerized by the attachment of a dimerization domain, such as leucine zippers.
  • Leucine zipper is a protein dimerization motif found in many eukaryotic transcription factors where it serves to bring two DNA-binding domains into appropriate juxtaposition for binding to transcriptional enhancer sequences. Dimerization of leucine zippers occurs via the formation of a short parallel coiled coil, with a pair of ⁇ -helices wrapped around each other in a superhelical twist. Zhu et al. (2000) J. MoI. Biol. 25 300: 1377-1387. These coiled-coil structures, named “leucine zippers” because of their preference for leucine in every 7th position, have also been used as dimerization devices in other proteins including antibodies. Hu et al.
  • Embodiments of the present invention may include amino acid sequence modification(s) of antibodies or fragments thereof. For example, it may be desirable to improve the binding affinity and/or other biological properties of the antibody.
  • Amino acid sequence variants of the antibody are prepared by introducing appropriate nucleotide changes into the antibody nucleic acid, or by peptide synthesis. Such modifications include, for example, deletions from, and/or insertions into and/or substitutions of, residues within the amino acid sequences of the antibody. Any combination of deletion, insertion, and substitution is made to arrive at the final construct, provided that the final construct possesses the desired characteristics.
  • the amino acid alterations may be introduced in the subject antibody amino acid sequence at the time that sequence is made.
  • a useful method for identification of certain residues or regions of the antibody that are preferred locations for mutagenesis is called "alanine scanning mutagenesis" as described by Cunningham and Wells (1989) Science, 244: 108 1-1085.
  • a residue or group of target residues is identified (e.g., charged residues such as Arg, Asp, His, Lys, and GIu) and replaced by a neutral or negatively charged amino acid (for example alanine or polyalanine) to affect the interaction of the amino acids with antigen.
  • Those amino acid locations demonstrating functional sensitivity to the substitutions may then be refined by introducing further or other variants at, or for, the sites of substitution.
  • Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues.
  • Non-limiting examples of terminal insertions include an antibody with an N-terminal methionyl residue or the antibody fused to a cytotoxic polypeptide.
  • insertional variants of the antibody molecule include the fusion to the N- or C-terminus of the antibody to an enzyme (e.g., for ADEPT) or a polypeptide which increases the serum half-life of the antibody.
  • an enzyme e.g., for ADEPT
  • Another type of variant is an amino acid substitution variant. These variants have at least one amino acid residue in the antibody molecule replaced by a different residue.
  • the sites of greatest interest for substitutional mutagenesis include the hypervariable regions, but FR alterations are also contemplated.
  • Substantial modifications in the biological properties of the antibody are accomplished by selecting substitutions that differ significantly in their effect on maintaining: (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain.
  • Naturally occurring residues are divided into groups based on common side-chain properties:
  • Non-conservative substitutions may entail exchanging a member of one of these classes for another class.
  • Any cysteine residue not involved in maintaining the proper conformation of the antibody may be substituted, generally with serine, to improve the oxidative stability of the molecule and prevent aberrant crosslinking. Conversely, cysteine bond(s) may be added to the antibody to improve its stability.
  • a particular type of substitutional variant involves substituting one or more hypervariable region residues of a parent antibody (e.g., a humanized or human antibody). Generally, the resulting variant(s) selected for further development will have improved biological properties relative to the parent antibody from which they are generated. A convenient way for generating such substitutional variants involves affinity maturation using phage display.
  • hypervariable region sites e.g., 6-7 sites
  • the antibodies thus generated are displayed from filamentous phage particles as fusions to the gene HI product of M 13 packaged within each particle.
  • the phage-displayed variants are then screened for their biological activity (e.g., binding affinity) as herein disclosed.
  • alanine scanning mutagenesis can be performed to identify hypervariable region residues contributing significantly to antigen binding.
  • Such contact residues and neighboring residues are candidates for substitution according to the techniques elaborated herein. Once such variants are generated, the panel of variants is subjected to screening as described herein and antibodies with superior properties in one or more relevant assays may be selected for further development.
  • Nucleic acid molecules encoding amino acid sequence variants of the antibody are prepared by a variety of methods known in the art. These methods include, but are not limited to, isolation from a natural source (in the case of naturally occurring amino acid sequence variants) or preparation by oligonucleotide-mediated (or site-directed) mutagenesis, PCR mutagenesis, and cassette mutagenesis of an earlier prepared variant or a non-variant version of the antibody.
  • the Fc region variant may comprise a human Fc region sequence (e.g., a human IgGl, IgG2, IgG3 or IgG4 Fc region) comprising an amino acid modification (e.g., a substitution) at one or more amino acid positions.
  • a human Fc region sequence e.g., a human IgGl, IgG2, IgG3 or IgG4 Fc region
  • an amino acid modification e.g., a substitution
  • the Fc region variant may display altered neonatal Fc receptor (FcRn) binding affinity.
  • FcRn neonatal Fc receptor
  • Such variant Fc regions may comprise an amino acid modification at any one or more of amino acid positions 238, 252, 253, 254, 255, 256, 265, 272, 286, 288, 303, 305, 307, 309, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, 386, 388, 400, 413, 415, 424, 433, 434, 435, 436, 439 or 447 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.
  • Fc region variants with reduced binding to an FcRn may comprise an amino acid modification at any one or more of amino acid positions 252, 253, 254, 255, 288, 309, 386, 388, 400, 415, 433, 435, 436, 439 or 447 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.
  • the above-mentioned Fc region variants may, alternatively, display increased binding to FcRn and comprise an amino acid modification at any one or more of amino acid positions 238, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, 413, 424 or 434 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.
  • the Fc region variant with reduced binding to an FcyR may comprise an amino acid modification at any one or more of amino acid positions 238, 239, 248, 249, 252, 254, 265, 268, 269, 270, 272, 278, 289, 292, 293, 294, 295, 296, 298, 301, 303, 322, 324, 327, 329, 333, 335, 338, 340, 373, 376, 382, 388, 389, 414, 416, 419, 434, 435, 437, 438 or 439 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.
  • the Fc region variant may display reduced binding to an Fc ⁇ RI and comprise an amino acid modification at any one or more of amino acid positions 238,265, 269, 270, 327 or 329 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.
  • the Fc region variant may display reduced binding to an Fc ⁇ RII and comprise an amino acid modification at any one or more of amino acid positions 238, 265, 269, 270, 292, 294, 295, 298, 303, 324, 327, 329, 333, 335, 338, 373, 376, 414, 416, 419, 435, 438 or 439 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.
  • the Fc region variant of interest may display reduced binding to an Fc ⁇ RIII and comprise an amino acid modification at one or more of amino acid positions 238, 239, 248, 249, 252, 254, 265, 268, 269, 270, 272, 278, 289, 293, 294, 295, 296, 301, 303, 322, 327, 329, 338, 340, 373, 376, 382, 388, 389, 416, 434, 435 or 437 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.
  • Fc region variants with altered (i.e. improved or diminished) CIq binding and/or Complement Dependent Cytotoxicity (CDC) are described in W099/51642.
  • Such variants may comprise an amino acid substitution at one or more of amino acid positions 270, 322, 326, 327, 329, 331, 333 or 334 of the Fc region. See, also, Duncan & Winter Nature 322:738-40 (1988); US Patent No. 5,648,260; US Patent No. 5,624,821; and W094129351 concerning Fc region variants.
  • the antibodies and antibody variants may be further modified to contain additional non-proteinaceous moieties that are known in the art and readily available. Derivatizations are especially useful for improving or restoring biological properties of the antibody or fragments thereof. For example, PEG modification of antibody fragments can alter the stability, in vivo circulating half life, binding affinity, solubility and resistance to proteolysis.
  • the moieties suitable for derivatization of the antibody may be are water soluble polymers.
  • Non-limiting examples of water soluble polymers may include, but are not limited to, polyethylene glycol (PEG), copolymers of ethylene glycol/propylene glycol, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-l,3-dioxolane, poly-l,3,6-trioxane, ethylene/maleic anhydride copolymer, polyamino acids (either homopolymers or random copolymers), and dextran or poly(n-vinyl pyrrolidone)polyethylene glycol, propropylene glycol homopolymers, polypropylene oxide/ethylene oxide co-polymers, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof.
  • PEG polyethylene glycol
  • copolymers of ethylene glycol/propylene glycol carboxymethylcellulose
  • dextran polyvinyl alcohol
  • Polyethylene glycol propionaldehyde may have advantages in manufacturing due to its stability in water.
  • the polymer may be of any molecular weight, and may be branched or unbranched.
  • the number of polymers attached to the antibody may vary, and if more than one polymer is attached, they may be the same or different molecules. In general, the number and or type of polymers used for derivatization may be determined based on considerations including, but not limited to, the particular properties or functions of the antibody to be improved, whether the antibody derivative will be used in a therapy under defined conditions.
  • the antibody or antibody fragment produced by a prokaryotic expression system as described herein may be aglycosylated and may lack detectable effector activities of the Fc region.
  • embodiments of the present invention contemplate a method for restoring the effector function(s) by attaching suitable moieties to identified residue sites in the Fc region of an aglycosylated antibody.
  • one moiety for this purpose may be PEG, although other carbohydrate polymers may also be used.
  • PEGylation may be carried out by any of the PEGylation reactions known in the art.
  • cysteine residues are first substituted for residues at identified positions of the antibody, such as those positions wherein the antibody or antibody variant is normally glycosylated or those positions on the surface of the antibody.
  • the cysteine may be substituted for residue(s) at one or more positions 297, 298, 299, 264, 265 and 239 (numbering according to the EU index as in Kabat).
  • the cysteine substituted antibody variant may have various forms of PEG (or pre-synthesized carbohydrate) chemically linked to the free cysteine residues.
  • binding region need not be derived from an antibody or antibody fragment.
  • Other natural (e.g., fibronectin, protein A derivatives) and non- natural (e.g., synthetic immunoglobulin folds, etc.) protein fragments/domains could be used as well.
  • the term binding region can be singular or plural.
  • identifying a binding region or “identifying a plurality of binding regions” refers to a plurality of antibodies and proteins comprising a plurality of unique immunoglobulins or antibody chains (e.g., heavy or light chains) (or other non-antibody binding proteins).
  • antibody or protein libraries comprise between about 10 6 to about 10 11 or even more unique antibodies or antibody chains or proteins.
  • the antigens thus displayed are exposed to antibody libraries for extended periods of time, typically two to twenty-four hours, as necessary for binding at one or more affinities. This allows each antibody in the library to bind the antigen to which it has highest affinity.
  • Bound antibodies and proteins are identified using one of a variety of approaches. For example, when using a phage display method antibodies or proteins are expressed in phage as fusions with a phage surface protein, resulting in the antibodies or proteins being displayed on the surface of the phage. A library of phage expressing different binding moieties is produced and bound to immobilized, target proteins in high throughput fashion. Phage with high affinity for target proteins are then isolated. Serial passages may be necessary to enrich for antibodies and proteins of interest.
  • the selected phage from one round are re-grown in bacteria, the new enriched phage culture is harvested, bound again to immobilized target proteins and the newly selected phage are re- isolated.
  • the isolated phage can be amplified for further testing and the sequence of the binding region determined.
  • Other methods known in the art for displaying antibodies or proteins may also be used in addition to phage display.
  • Several types of antibody or protein libraries may be used for screening, including single chain, phage display, and potentially a two chain antibody library generated through a strategy described below. Humanized antibodies and proteins may be used so that they can be used for therapeutic purposes.
  • Antibody and protein libraries are commercially available from a number of sources. Binding regions may be identified via alternative methods as known in the art.
  • binding sites may be identified via ribosome display, yeast display, bacterial display, and rriRNA display.
  • the term "fusing the binding region to a plurality of scaffolds of antibody constant regions” refers to fusion of one or more binding regions (antibody light and heavy chain variable regions, or other natural or non-natural binding domain) or fused to scaffolds other than antibody constant regions to scaffolds of antibody constant regions as seen in FIG. 5. Fusion of antibody binding regions to scaffolds of antibody constant regions may be achieved by, for example, SOE-PCR, direct gene synthesis, or cloning of binding regions in frame with scaffold structures present in pre-constructed vectors. After an antibody binding region is fused to scaffolds of antibody constant regions an antibody fragment variant may be obtained.
  • these antibody fragment variants or "scaffolds” may include F(ab') 2 , Fab', Fab, mAb, diabody, scFv, stabilized scFv, or scFv multimers. While previous methods included comparisons of limited number of host strains or regulatory elements in more or less sequential fashion, embodiments according to the present invention show that multiple scaffolds for the same binding domain may be fused to that binding domain and rapidly screened to identify good producers that can be scaled up and tested for efficacy. Alternatively, a single molecule may be screened rapidly in hundreds of host strains in parallel to identify the optimal production strain.
  • protein herein is meant at least two amino acids linked together by a peptide bond.
  • protein includes proteins, oligopeptides and peptides.
  • the peptidyl group may comprise naturally occurring amino acids and peptide bonds, or synthetic peptidomimetic structures, i.e. "analogs", such as peptoids (see Simon et al., PNAS USA 89(20):9367 (1992)).
  • the amino acids may either be naturally occurring or non-naturally occurring; as will be appreciated by those in the art, any structure for which a set of rotamers is known or can be generated can be used as an amino acid.
  • the side chains may be in either the (R) or the (S) configuration. In an embodiment, the amino acids are in the (S) or L- configuration.
  • the scaffold protein may be any protein for which a three dimensional structure is known or can be generated; that is, for which there are three dimensional coordinates for each atom of the protein. Generally, this can be determined using X-ray crystallographic techniques, NMR techniques, de novo modeling, homology modeling, etc. In general, if X-ray structures are used, structures may be, for example, at 2 A resolution.
  • the scaffold proteins may be from any organism, including prokaryotes and eukaryotes, with enzymes from bacteria, fungi, extremeophiles such as the archebacteria, insects, fish, animals (for example mammals or human) and birds all possible.
  • scaffold protein herein is meant a protein for which a library of variants may exist.
  • any number of scaffold proteins find use in the embodiments of the present invention.
  • fragments and domains of known proteins or antibodies including functional domains such as enzymatic domains, binding domains, etc., and smaller fragments, such as turns, loops, etc. That is, portions of proteins may be used as well.
  • protein as used herein includes proteins, oligopeptides and peptides.
  • protein variants i.e. non- naturally occurring protein analog structures, may be used.
  • Suitable proteins include, but are not limited to, industrial and pharmaceutical proteins, including ligands, cell surface receptors, antigens, antibodies, cytokines, hormones, transcription factors, signaling modules, cytoskeletal proteins and enzymes.
  • Suitable classes of enzymes include, but are not limited to, hydrolases such as proteases, carbohydrases, lipases; isomerases such as racemases, epimerases, tautomerases, or mutases; transferases, kinases, oxidoreductases, and phosphatases.
  • Suitable enzymes are listed in the Swiss-Prot enzyme database.
  • Suitable protein backbones include, but are not limited to, all of those found in the protein data base compiled and serviced by the Research Collaboratory for Structural Bioinformatics (RCSB, formerly the Brookhaven National Lab).
  • scaffold proteins may include, but are not limited to, those with known structures (including variants) including cytokines (IL- Ira (+receptor complex), IL-I (receptor alone), IL-Ia, IL-Ib (including variants and or receptor complex), IL-2, IL-3, IL-4, IL- 5, IL6, IL-8, IL-10, IFN- ⁇ , INF- ⁇ , IFN- ⁇ -2a; IFN- ⁇ -2B, TNF- ⁇ ; CD40 ligand (chk), Human Obesity Protein Leptin, Granulocyte-Macrophage Colony-Stimulating Factor, Bone Morphogenetic Protein-7, Ciliary Neurotrophic Factor, Granulocyte-Macrophage Colony- Stimulating Factor, Monocyte Chemoattractant Protein 1, Macrophage Migration Inhibitory Factor, Human Glycosylation-Inhibiting Factor, Human Rantes, Human Macrophage Inflammatory Protein 1 Beta, human
  • cytokines
  • Erythropoietin other extracellular signaling moieties, including, but not limited to, hedgehog Sonic, hedgehog Desert, hedgehog Indian, hCG; coagulation factors including, but not limited to, TPA and Factor Vila; transcription factors, including but not limited to, p53, p53 tetramerization domain, Zn fingers (of which more than 12 have structures), homeodomains (of which 8 have structures), leucine zippers (of which 4 have structures); antibodies, including, but not limited to, cFv; viral proteins, including, but not limited to, hemagglutinin trimerization domain and HIV Gp41 ectodomain (fusion domain); intracellular signaling modules, including, but not limited to, SH2 domains (of which 8 structures are known), SH3 domains (of which 11 have structures), and Pleckstin Homology Domains; receptors, including, but not limited to, the extracellular Region Of Human Tissue Factor Cytokine-Binding Region Of Gp 130,
  • the antibody fragment variants according to the embodiments of the present invention may be expressed in a host cell or host organism, i.e. for expression and/or production of a construct.
  • Suitable hosts or host cells will be clear to the skilled person, and may for example be any suitable fungal, prokaryotic or eukaryotic cell or cell line or any suitable fungal, prokaryotic or eukaryotic organism, for example: a bacterial strain, including but not limited to gram-negative strains such as strains of Escherichia coli; of Proteus, for example of Proteus mirabilis; of Pseudomonas, for example of Pseudomonas fluorescens; and gram-positive strains such as strains of Bacillus, for example of Bacillus subtilis or of Bacillus brevis; of Streptomyces, for example of Streptomyces lividans; of Staphylococcus, for example of Staphylococcus carnosus; and
  • PFENEX EXPRESSION TECHNOLOGYTM is a Pseudomonas fluorescens-based expression system that increases cellular expression while maintaining certain solubility and activity characteristics due to its use of different pathways in the metabolism of certain sugars compared to E. coli.
  • PFENEX EXPRESSION TECHNOLOGYTM is a Pseudomonas fluorescens-based expression system that increases cellular expression while maintaining certain solubility and activity characteristics due to its use of different pathways in the metabolism of certain sugars compared to E. coli.
  • Expression of mammalian proteins via a Pseudomonas based expression system is described, for instance, in US Patent Application 20060234346 and US Patent Application 20060040352, the contents of which are hereby incorporated by reference.
  • Antibody fragment variants may be expressed in Pseudomonas ⁇ uorescens utilizing PFENEX EXPRESSION TECHNOLOGYTM components such as, for example, multiple promoter secretion signals, ribosome binding sites, protease knockout hosts, transcriptional/translational regulatory protein knockout or overexpression hosts, and folding modulator overexpression hosts.
  • PFENEX EXPRESSION TECHNOLOGYTM components such as, for example, multiple promoter secretion signals, ribosome binding sites, protease knockout hosts, transcriptional/translational regulatory protein knockout or overexpression hosts, and folding modulator overexpression hosts.
  • preferred heterologous hosts for the (industrial) production of constructs of the invention include strains of E. coli, Pichia pastoris, S. cerevisiae or P. fluorescens that are suitable for large scale expression/production/fermentation, and in particular for large scale pharmaceutical expression/production/fermentation. Suitable examples of such strains will be clear to the skilled person. Such strains and production/expression systems are also made available by companies such as Dowpharma and Biovitrum (Uppsala, Sweden).
  • Induced cultures may be formed by expressing the previously formed construct carried by the organism or cell, for example P. fluorescens, in high throughput (HTP) mode.
  • the induced cultures may be evaluated for both binding strength and protein yield by utilizing ELISA based tests, biolayer interferometry, or similar methods.
  • optimal product candidates and production strains may be identified in a single screen.
  • multiple fragment types of a single binding region may be identified and screened in animal models to evaluate the fragment type that provides optimal bioavailability, half life, and reduced immunogenicity.
  • multiple binding regions fused to one or more scaffolds, or constructed as scFvs, diabodies, or similar constructs may be screened in a similar fashion.
  • a protein's functionality depends upon complex, subtle, and sensitive interactions among all of its parts. Thus, a single amino acid change made in a protein of any size may seriously or completely disrupt its folding and activity. Methods currently employed to discover and then further develop antibody binding domains into biologically and pharmacologically active compounds suffer from this disruptive gap. They are severely limited by the fact that the steps between discovery and development reside in two different protein structural platforms resulting in a disconnect between the functionality of the binding domain in the discovery platform versus the functionality of the binding domain in the development platform. Embodiments of the present invention may narrow the disconnection between the platforms by building many more degrees of freedom into the development process, allowing many more combinations of functional molecules to be tested in parallel. Therefore, a more rapid development of robust binding molecules for functional and pre-clinical testing may be achieved.
  • IPTG Isopropyl- ⁇ -D-1-thiogalactopyranoside
  • a swinging bucket centrifuge model CR422, Jouan, Inc., Winchester, VA
  • Streptavidin High Binding biosensors (ForteBio # 18-0006) were hydrated in kinetics buffer (ForteBio), then loaded with lO ⁇ g/mL biotin- ⁇ -galactosidase (Sigma #G5025 lot #034K6020) for 2 hours, rinsed in kinetics buffer a few minutes, then pre-equilibrated in 25% DC432 soluble fraction for 25 minutes before starting assay.
  • the standards (mAb anti- ⁇ -galactosidase, Sigma #G8021; purified Gall3 scFv; purified Gal 13 diabody) were diluted into 25% empty vector control soluble fraction.
  • the test samples were diluted 2-fold into kinetics buffer (PBS/0.01%BSA/0.001%Tween). The samples were pre-equilibrated at 3O 0 C for 10 minutes, and the assay was started. Samples were read at 3O 0 C for 180 seconds with a mixing rate of lOOOrpm.
  • Streptavidin High Binding biosensors (ForteBio # 18-0006) were hydrated in kinetics buffer (ForteBio), then loaded with 4ug/mL biotinylated ligand (5(6)- (biotinamidohexanoyl-amido)pentylthioureidyl-fluorescein, Sigma cat# B8889-1MG) diluted into Ix kinetics buffer for 30 minutes. The test samples were diluted 2-fold into kinetics buffer (PBS/0.01%BSA/0.001%Tween). The samples were pre-equilibrated at 3O 0 C for 10 minutes, and the assay was started.
  • variable domains of the Gal2 and Gall3 scFvs (1-3) were fused to human IgGl constant regions to produce a monoclonal antibody and antibody fragment derivatives, as well as fused directly with a linker of 4 glycine and one serine to produce a diabody as seen in FIG. 1
  • FIG. 1 shows a histogram of optical density readings at 600nm of cultures taken 24 hours post induction. Expression of each protein was directed to the periplasmic space via the phosphate binding protein secretion leader (4). A total of 4 antibody derivatives were constructed for each ⁇ -galactosidase binding region (Table 1). Expression of each was tested in P. fluorescens DC454 to assess yield of active protein.
  • FIG. 2 shows specific expression of anti- ⁇ -galactosidase antibody derivatives. Specific yield for each replicate is shown, expressed as the natural log of the yield ( ⁇ g/mL) per optical density unit. As shown in FIG. 2, the highest yields of active protein were detected from those strains expressing scFv or Fab derivatives (DC 351, DC596, DC589, DC698 and DC699). No active Gal2 mAb was detected; however, cell densities were very low. Small amounts of active Gal 13 mAb and diabody were detected.
  • a DNA fragment containing the heavy chain (gene 1), bidirectional transcriptional terminator and light chain (gene 2) was cloned into a library of 74 expression vectors with combinations of 2 promoters, 3 ribosome binding sites (RBS) and 3 secretion leaders.
  • the DNA fragment can be cloned in either orientation allowing for 148 possible combinations.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des procédés d'identification et d'expression d'un variant d'anticorps, le procédé comprenant les étapes consistant à identifier une région de liaison dans un anticorps, relier la région de liaison à une pluralité de structures de régions constantes d'un anticorps afin d'obtenir des variants de fragments d'anticorps, exprimer les variants de fragments d'anticorps dans des organismes afin de former des constructions et exprimer les constructions portées par les organismes afin de former des cultures induites, les organismes étant exprimés dans le mode HTP.
PCT/US2009/049366 2008-07-03 2009-07-01 Procédé de criblage à haut débit et son utilisation pour identifier une plateforme de production d'une protéine de liaison multifonctionnelle WO2010002966A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA2729839A CA2729839A1 (fr) 2008-07-03 2009-07-01 Procede de criblage a haut debit et son utilisation pour identifier une plateforme de production d'une proteine de liaison multifonctionnelle
NZ590619A NZ590619A (en) 2008-07-03 2009-07-01 High throughput screening method and use thereof to identify a production platform for a multifunctional binding protein
EP09774416A EP2313507A2 (fr) 2008-07-03 2009-07-01 Procédé de criblage à haut débit et son utilisation pour identifier une plateforme de production d'une protéine de liaison multifonctionnelle
AU2009266989A AU2009266989B2 (en) 2008-07-03 2009-07-01 High throughput screening method and use thereof to identify a production platform for a multifunctional binding protein
US13/001,913 US20110111977A1 (en) 2008-07-03 2009-07-01 High throughput screening method and use thereof to identify a production platform for a multifunctional binding protein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7829208P 2008-07-03 2008-07-03
US61/078,292 2008-07-03

Publications (2)

Publication Number Publication Date
WO2010002966A2 true WO2010002966A2 (fr) 2010-01-07
WO2010002966A3 WO2010002966A3 (fr) 2010-07-22

Family

ID=41100528

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/049366 WO2010002966A2 (fr) 2008-07-03 2009-07-01 Procédé de criblage à haut débit et son utilisation pour identifier une plateforme de production d'une protéine de liaison multifonctionnelle

Country Status (6)

Country Link
US (1) US20110111977A1 (fr)
EP (1) EP2313507A2 (fr)
AU (1) AU2009266989B2 (fr)
CA (1) CA2729839A1 (fr)
NZ (1) NZ590619A (fr)
WO (1) WO2010002966A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018226880A1 (fr) * 2017-06-06 2018-12-13 Zymergen Inc. Plate-forme d'ingénierie génomique htp permettant d'améliorer escherichia coli
WO2018226893A3 (fr) * 2017-06-06 2019-01-10 Zymergen Inc. Plate-forme d'ingénierie génomique à haut rendement (htp) pour l'amélioration de saccharopolyspora spinosa

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9567596B2 (en) 2012-01-05 2017-02-14 Glykos Finland Oy Protease deficient filamentous fungal cells and methods of use thereof
DK2852610T3 (en) 2012-05-23 2018-09-03 Glykos Finland Oy PRODUCTION OF FUCOSYLED GLYCOPROTEIN
JP2016523552A (ja) 2013-07-10 2016-08-12 ノバルティス アーゲー 多重プロテアーゼ欠損糸状菌細胞及びその使用方法
WO2016012468A1 (fr) 2014-07-21 2016-01-28 Novartis Ag Production de glycoprotéines avec des n-glycanes de type mammifère dans des champignons filamenteux

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994025609A1 (fr) * 1993-04-28 1994-11-10 Hybritech Incorporated Procede de production de regions regulatrices optimalisees affectant l'expression et le ciblage des proteines
WO2001094418A2 (fr) * 2000-06-05 2001-12-13 Corixa Corporation Nouvelles peptides de tete permettant d'augmenter la secretion d'une proteine recombinee dans une cellule hote
WO2001098453A2 (fr) * 2000-06-22 2001-12-27 Pierre Fabre Medicament Vecteurs d'expression comprenant un fragment modifie de l'operon tryptophane
WO2003089621A2 (fr) * 2002-04-22 2003-10-30 E. I. Du Pont De Nemours And Company Systemes de promoteurs et de plasmides pour l'ingenierie genetique
WO2003089605A2 (fr) * 2002-04-22 2003-10-30 Genencor International, Inc. Methode de creation d'une bibliotheque de clones bacteriens avec differents niveaux d'expression genique
WO2009020899A1 (fr) * 2007-08-03 2009-02-12 Dow Global Technologies Inc. Séquences de régions d'initiation de la traduction pour une expression optimale de protéines hétérologues
WO2009112587A2 (fr) * 2008-03-14 2009-09-17 Merck Serono S.A. Variation de titres d'expression recombinante par optimisation de sites de liaison à des ribosomes bactériens

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1988007089A1 (fr) * 1987-03-18 1988-09-22 Medical Research Council Anticorps alteres
US5641870A (en) * 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US9453251B2 (en) * 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994025609A1 (fr) * 1993-04-28 1994-11-10 Hybritech Incorporated Procede de production de regions regulatrices optimalisees affectant l'expression et le ciblage des proteines
WO2001094418A2 (fr) * 2000-06-05 2001-12-13 Corixa Corporation Nouvelles peptides de tete permettant d'augmenter la secretion d'une proteine recombinee dans une cellule hote
WO2001098453A2 (fr) * 2000-06-22 2001-12-27 Pierre Fabre Medicament Vecteurs d'expression comprenant un fragment modifie de l'operon tryptophane
WO2003089621A2 (fr) * 2002-04-22 2003-10-30 E. I. Du Pont De Nemours And Company Systemes de promoteurs et de plasmides pour l'ingenierie genetique
WO2003089605A2 (fr) * 2002-04-22 2003-10-30 Genencor International, Inc. Methode de creation d'une bibliotheque de clones bacteriens avec differents niveaux d'expression genique
WO2009020899A1 (fr) * 2007-08-03 2009-02-12 Dow Global Technologies Inc. Séquences de régions d'initiation de la traduction pour une expression optimale de protéines hétérologues
WO2009112587A2 (fr) * 2008-03-14 2009-09-17 Merck Serono S.A. Variation de titres d'expression recombinante par optimisation de sites de liaison à des ribosomes bactériens

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
BANDMANN NINA ET AL: "Combinatorial expression vector engineering for tuning of recombinant protein production in Escherichia coli" NUCLEIC ACIDS RESEARCH, vol. 35, no. 5, 2007, page Article No.: E32, XP002548137 ISSN: 0305-1048 *
BARRICK D ET AL: "Quantitative analysis of ribosome binding sites in E.coli" NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 22, no. 7, 11 April 1994 (1994-04-11), pages 1287-1295, XP002504099 ISSN: 0305-1048 *
CHOI B-K ET AL: "Use of combinatorial genetic libraries to humanize N-linked glycosylation in the yeast Pichia pastoris" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 100, no. 9, 29 April 2003 (2003-04-29), pages 5022-5027, XP002267831 ISSN: 0027-8424 *
HARTNER FRANZ S ET AL: "Promoter library designed for fine-tuned gene expression in Pichia pastoris" NUCLEIC ACIDS RESEARCH, vol. 36, no. 12, July 2008 (2008-07), page Article No.: e76, XP002548135 ISSN: 0305-1048 *
LI ET AL: "A comparative study of different vector designs for the mammalian expression of recombinant IgG antibodies" JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 318, no. 1-2, 3 January 2007 (2007-01-03), pages 113-124, XP005820142 ISSN: 0022-1759 *
RETALLACK DIANE M ET AL: "Transport of heterologous proteins to the periplasmic space of Pseudomonas fluorescens using a variety of native signal sequences" BIOTECHNOLOGY LETTERS, KEW, SURREY, GB, vol. 29, no. 10, 1 October 2007 (2007-10-01), pages 1483-1491, XP002483316 ISSN: 0141-5492 [retrieved on 2007-05-31] *
SCHLARB B G ET AL: "Expression of plastocyanin and cytochrome f of the cyanobacterium Phormidium laminosum in Escherichia coli and Paracoccus denitrificans and the role of leader peptides" GENE, ELSEVIER, AMSTERDAM, NL, vol. 234, no. 2, 8 July 1999 (1999-07-08), pages 275-283, XP004173099 ISSN: 0378-1119 *
SCHUMANN WOLFGANG ET AL: "Production of recombinant proteins in Escherichia coli" GENETICS AND MOLECULAR BIOLOGY, vol. 27, no. 3, September 2004 (2004-09), pages 442-453, XP002548138 ISSN: 1415-4757 *
SORIANO ELENA ET AL: "Optimization of recombinant protein expression level in Escherichia coli by flow cytometry and cell sorting" BIOTECHNOLOGY AND BIOENGINEERING, vol. 80, no. 1, 5 October 2002 (2002-10-05), pages 93-99, XP002548136 ISSN: 0006-3592 *
WEGERER ANGELIKA ET AL: "Optimization of an E. coli L-rhamnose-inducible expression vector: test of various genetic module combinations" BMC BIOTECHNOLOGY, BIOMED CENTRAL LTD. LONDON, GB, vol. 8, no. 1, 14 January 2008 (2008-01-14), page 2, XP021035689 ISSN: 1472-6750 *
WILSON ET AL: "Increased Protein Expression Through Improved Ribosome-Binding Sites Obtained by Library Mutagenesis" BIOTECHNIQUES, INFORMA LIFE SCIENCES PUBLISHING, WESTBOROUGH, MA, US, vol. 17, no. 5, 1 January 1994 (1994-01-01), pages 944-953, XP002161835 ISSN: 0736-6205 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018226880A1 (fr) * 2017-06-06 2018-12-13 Zymergen Inc. Plate-forme d'ingénierie génomique htp permettant d'améliorer escherichia coli
WO2018226893A3 (fr) * 2017-06-06 2019-01-10 Zymergen Inc. Plate-forme d'ingénierie génomique à haut rendement (htp) pour l'amélioration de saccharopolyspora spinosa

Also Published As

Publication number Publication date
WO2010002966A3 (fr) 2010-07-22
AU2009266989B2 (en) 2013-05-02
EP2313507A2 (fr) 2011-04-27
NZ590619A (en) 2012-08-31
US20110111977A1 (en) 2011-05-12
AU2009266989A1 (en) 2010-01-07
CA2729839A1 (fr) 2010-01-07

Similar Documents

Publication Publication Date Title
Könning et al. Beyond antibody engineering: directed evolution of alternative binding scaffolds and enzymes using yeast surface display
AU2009266989B2 (en) High throughput screening method and use thereof to identify a production platform for a multifunctional binding protein
US11332735B2 (en) Method of improving characteristics of proteins
Pardon et al. A general protocol for the generation of Nanobodies for structural biology
US20170335016A1 (en) Stable multivalent antibody
JP5372992B2 (ja) ユビキチンタンパク質に基づく人工結合タンパク質の生成
JP5049383B2 (ja) ポリペプチドレパートリーから可逆的にアンフォールドするポリペプチドを回収するための方法
JP5508002B2 (ja) 免疫グロブリンのエンジニアリング方法
CN101679974A (zh) 包含抗体替代轻链序列的构建体和文库
CN109535254B (zh) 抗人bdca-2抗体、其生产方法、多核苷酸、表达载体、宿主细胞及医药组合物
JP5959438B2 (ja) 疾患を治療するための剤
CN113272651B (zh) 鉴别蛋白质中的游离巯基的方法
RU2670491C2 (ru) Система экспрессии и секреции
IL265995B1 (en) A ternary vector expressing antibodies in a fully therapeutic configuration
Chen et al. Synthetic antibodies and peptides recognizing progressive multifocal leukoencephalopathy-specific point mutations in polyomavirus JC capsid viral protein 1
EP2619578B1 (fr) Procédé d'analyse d'interactions de liaison
CN113711037A (zh) 抗体效力测定
EP2501808B1 (fr) Présentation de protéines dimères à liaison disulfure sur phage filamenteux
US20100233167A1 (en) Chain reaction creating oligomers from repeat units of binding molecules
Alvarenga et al. Recombinant antibodies: trends for standardized immunological probes and drugs
Schofield Recombinant Antibodies–7 key insights to rAbs

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09774416

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 13001913

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2729839

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009266989

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 590619

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2009774416

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2009266989

Country of ref document: AU

Date of ref document: 20090701

Kind code of ref document: A